Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis
Open Access
- 1 November 2016
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15 (6) , 783-790
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation (KONSTA09Y0)
- National Institutes of Health (UL1TR000439, P30 DK027651)
- South Carolina Clinical & Translational Research (SCTR) Institute
- National Institutes of Health (UL1TR001450)
This publication has 20 references indexed in Scilit:
- Location and Duration of Treatment of Cystic Fibrosis Respiratory ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centersPediatric Pulmonology, 2011
- Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Healthcare expenditures for privately insured people with cystic fibrosisPediatric Pulmonology, 2009
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007
- Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosisPediatric Pulmonology, 2006
- Cystic fibrosis pulmonary exacerbationsThe Journal of Pediatrics, 2006
- One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Factors Influencing Outcomes in Cystic FibrosisChest, 2003
- Impact of Recent Pulmonary Exacerbations on Quality of Life in Patients With Cystic FibrosisChest, 2002